SABCS 2022 | Effectiveness of ICIs in the neoadjuvant and post-neoadjuvant breast cancer setting

Lajos Pusztai, MD, Yale School of Medicine, New Haven, CT, discusses the effectiveness of immune checkpoint inhibitors in the neoadjuvant and post-neoadjuvant breast cancer setting. A series of neoadjuvant trials demonstrated an improvement in pathologic complete response (pCR) rate with the addition an immune inhibitor, although the improvement in pCR rate was only relatively modest. Despite the small improvement in pCR rate, there was, however, a significant and clinical meaningful improvement in recurrence-free survival (RFS), an important clinical endpoint in adjuvant trials. For instance, the Phase III KEYNOTE-522 (NCT03036488) trial demonstrated statistically significant and clinically meaningful improvement in pCR and event-free survival (EFS) rates in patients with early triple-negative breast cancer (TNBC) with the addition of pembrolizumab to neoadjuvant chemotherapy followed by an adjuvant phase. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.